Search Constraints
« Previous |
21 - 40 of 80
|
Next »
Search Results
Select an image to start the slideshow
Development of chemical probes for non-BET bromodomains
1 of 20
Use of fragment-based drug discovery to identify novel drug molecules for challenging biological targets, including protein-protein interactions
2 of 20
Investigation and application of 3-Oxabicyclo[4.1.0]heptane as a mechanistic target of rapamycin (mTOR) kinase hinge binding fragment
3 of 20
The development of small molecules for treatment of idiopathic pulmonary fibrosis (IPF)
4 of 20
The design, synthesis and optimisation of epigenetic mechanism inhibitors
5 of 20
Sustainable cross-couplings for pharmaceutical scale-up using aryldiazonium salts
6 of 20
The design, synthesis and optimisation of kinase inhibitors as potential anti-inflammatory agents
7 of 20
New hydrogen atom transfer methodologies for synthesis
8 of 20
Investigations of the synthesis and properties of romodomain and extra-terminal domain proteolysis targeting chimeras
9 of 20
The use of contemporary chemoproteomic techniques in antimalarial target identification
10 of 20
Preclinical development of a treatment for systemic lupus erythematosus
11 of 20
The design and synthesis of novel epigenetic modulators
12 of 20
Design and synthesis of dimethylisoxazole quinolines as BET inhibitors
13 of 20
The development of chemo- and regioselective reactions of boron systems
14 of 20
New chemical approaches for the development of targeted protein degradation
15 of 20
Targeted protein degradation as a new approach to drug discovery
16 of 20
The design and synthesis of probe molecules to validate the inhibition of epigenetic mechanisms for phenotypic responses
17 of 20
The synthesis and optimisation of toll-like receptor agonists as potential immunomodulatory agents
18 of 20
The design, synthesis and optimisation of phosphoinositide-3-kinase (PI3K) inhibitors as potential anti-inflammatory agents
19 of 20
The design, synthesis and optimisation of calcium release-activated calcium (CRAC) channel inhibitors and mitochondrial permeability transition pore (mPTP) modulators, using phenotypic screening
20 of 20